论文部分内容阅读
目的观察吡柔比星为主联合化疗在老年非霍奇金淋巴瘤患者治疗中的临床效果。方法 60例老年非霍奇金淋巴瘤患者,依照患者治疗方式分成对照组和观察组,各30例。对照组患者实施阿霉素为主联合化疗,观察组患者实施吡柔比星为主联合化疗,对比两组患者的临床治疗效果。结果观察组患者的总缓解率为93.3%(28/30),显著高于对照组的73.3%(22/30),差异具有统计学意义(P<0.05)。观察组患者的毒副反应发生率为30.0%(9/30),显著低于对照组的60.0%(18/30),差异具有统计学意义(P<0.05)。结论吡柔比星为主结合化疗治疗老年非霍奇金淋巴瘤患者临床效果显著,能够显著降低患者的毒副作用发生率,值得临床推广。
Objective To observe the clinical effect of pirarubicin-based combination chemotherapy in the treatment of elderly patients with non-Hodgkin’s lymphoma. Methods Sixty elder patients with non-Hodgkin’s lymphoma were divided into control group and observation group according to patients’ treatment. Patients in the control group received doxorubicin-based combination chemotherapy. Patients in the observation group received pirarubicin-based combination chemotherapy, comparing the clinical effects of the two groups. Results The total remission rate in the observation group was 93.3% (28/30), which was significantly higher than that in the control group (73.3%, 22/30). The difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 30.0% (9/30), which was significantly lower than that in the control group (60.0%, 18/30). The difference was statistically significant (P <0.05). Conclusion Pirarubicin combined with chemotherapy in the treatment of elderly patients with non-Hodgkin’s lymphoma significant clinical effect, can significantly reduce the incidence of toxic and side effects in patients, it is worth clinical promotion.